Indivior二季度收入和盈利超预期并上调全年指引

Oil falls over 5% as Trump calls off Iran strike, announces fresh talks
Introduction & Market Context
Indivior PLC (NASDAQ:INDV) presented its second-quarter 2026 financial results on August 3, revealing substantial margin expansion and accelerating growth in its flagship opioid use disorder treatment SUBLOCADE. The presentation detailed the company’s progress through its three-phase strategic plan and outlined the proposed merger with Supernus Pharmaceuticals, which management positioned as the culmination of Phase III of its "Indivior Action Agenda."
The company’s shares traded at $39.33, down 1.7% from the previous close of $40.01, despite delivering results that significantly exceeded analyst expectations. With adjusted earnings per share of $1.15 versus estimates of $0.74 and revenue of $343 million versus forecasts of $284.9 million, the modest stock decline likely reflects investor caution around merger execution risk rather than operational concerns.
Quarterly Performance Highlights
As shown in the following summary of Q2 2026 business performance, Indivior delivered double-digit growth across key metrics while more than doubling its adjusted EBITDA.
Total net revenue reached $343 million in the second quarter, representing 14% year-over-year growth from $302 million in Q2 2025. SUBLOCADE net revenue climbed 21% to $253 million from $209 million, while adjusted EBITDA surged 111% to $186 million from $88 million. The adjusted EBITDA margin expanded dramatically from 29% to 54%, a 25-percentage-point improvement driven by both revenue growth and aggressive cost management.
The company’s GAAP net income jumped 574% to $122 million from $18 million in the prior-year period, while non-GAAP net income increased 122% to $142 million from $64 million. The substantial improvement in profitability reflects the successful execution of organizational simplification efforts initiated in Phase I of the company’s action agenda.
The following detailed financial breakdown illustrates the comprehensive nature of Indivior’s operational improvements across revenue, margins, and expense management.
Non-GAAP operating expenses declined 33% to $112 million from $167 million, with selling, general and administrative expenses falling 27% and research and development expenses dropping 72%. The company achieved a non-GAAP gross margin of 87%, up 300 basis points from 84% in the prior year.
SUBLOCADE Commercial Momentum
SUBLOCADE, Indivior’s extended-release buprenorphine injection for opioid use disorder, continued to demonstrate strong commercial traction across multiple metrics. The following chart details the product’s performance across key operational indicators.
Trailing twelve-month SUBLOCADE patients increased 17% year-over-year to 199,800, while dispense units grew 18% to 195,400 in the quarter. The prescriber base expanded 18% to 9,800 healthcare providers, with the number of prescribers treating five or more patients rising 18% to 3,900. More than 545,000 U.S. patients have been prescribed SUBLOCADE since launch, and the product maintained a 76% share of the U.S. long-acting injectable category for the sixth or seventh consecutive quarter.
New patient starts accelerated 27% year-over-year in Q2 2026, suggesting strengthening demand momentum. Management attributed this growth to improved commercial execution, expanded patient awareness through direct-to-consumer campaigns, and policy initiatives aimed at increasing access to long-acting injectable treatments.
The company’s sustained commercial initiatives, illustrated in the following overview, focused on three strategic pillars: improving commercial execution, expanding patient engagement, and unlocking access through policy leadership.
On the commercial execution front, 10% of new patients received an accelerated second dose by the end of Q2 2026, with 25% of active healthcare providers having begun prescribing the accelerated dosing regimen. The company executed five agreements with specialty pharmacy partners expected to improve commercial dispense yields.
Patient engagement efforts included a direct-to-consumer campaign driving more than 1,300 customer relationship management enrollments per month, while over 34,000 people utilized the "Find A SUBLOCADE Treatment Provider" physician locator in the quarter.
Strategic Action Agenda Progress
Indivior’s presentation emphasized progress through its three-phase strategic framework, which management branded as "THE INDIVIOR ACTION AGENDA." The following visual representation outlines the evolution from momentum generation through acceleration to the current "Breakout" phase.
Phase I, labeled "Generate Momentum," focused on growing U.S. SUBLOCADE revenue, simplifying the organization, and determining necessary investments to expand long-acting injectable penetration. Phase II, "Accelerate," which began January 1, 2026, aimed to accelerate SUBLOCADE dispense units and net revenue while immediately improving adjusted EBITDA and cash flow. Phase III, "Breakout," which commenced July 1, 2026, centers on leveraging the strengthened financial profile to acquire next growth drivers.
The company’s accomplishments across these phases are detailed in the following comprehensive summary.
SUBLOCADE dispense unit growth is expected to reach 20% in 2026, up from 7% in 2025, with total SUBLOCADE net revenue projected to increase 20% to approximately $1,030 million. The organizational simplification resulted in non-GAAP operating expenses capped at $450 million, while cash flow from operations is expected to reach approximately $420 million in 2026. Adjusted EBITDA is forecast to increase 68% to $720 million, with the margin expanding from 35% to 54%.
Capital Deployment Strategy
Indivior demonstrated active capital management during the quarter, returning $175 million to shareholders through the repurchase of approximately 4.7 million shares at an average price of $37.52. Over the past year, the company has returned $300 million through the repurchase of more than 8.6 million shares at an average price of $34.73.
The following illustration outlines the company’s comprehensive capital deployment framework and available resources.
As of June 30, 2026, Indivior held $249 million in cash and investments, with expected cash flow from operations of approximately $420 million for the full year. In March 2026, the company completed an offering of $500 million in convertible senior notes due in 2031, using proceeds to repay a $333 million term loan and improve debt terms.
Supernus Merger and Growth Strategy
The proposed all-stock merger with Supernus Pharmaceuticals represents the centerpiece of Phase III of Indivior’s action agenda. The following slide details the strategic rationale for the combination.
The merger is expected to enhance and diversify the growth profile, providing a differentiated portfolio with durable growth into the 2030s while establishing four commercial beachheads across addiction, ADHD, depression, and Parkinson’s disease. Management projects immediate increased scale from significant cost synergies and greater flexibility to pursue growth initiatives.
On a pro forma trailing twelve-month basis through June 30, 2026, the combined company would generate approximately $2.2 billion in net revenue and $888 million in adjusted EBITDA, including $125 million in expected annual cost synergies. The pro forma adjusted EBITDA margin would be approximately 41%, with net debt of $878 million and approximately 215 million fully diluted shares outstanding.
Under the transaction terms, Supernus shareholders would receive 1.5401 shares of Indivior for each Supernus share. The combined company will retain the Supernus name and be headquartered in Rockville, Maryland, with the transaction expected to close in the fourth quarter of 2026 pending shareholder and regulatory approvals.
Raised Financial Guidance
Based on the strong first-half performance and momentum in SUBLOCADE, Indivior raised its full-year 2026 financial guidance across multiple metrics. The following comparison illustrates the magnitude of the upward revisions.
Total net revenue guidance increased to a range of $1,295 million to $1,365 million from the previous range of $1,215 million to $1,285 million, representing expected year-over-year growth of 7%. SUBLOCADE net revenue guidance was raised to $1,010 million to $1,050 million from $950 million to $990 million, implying 20% year-over-year growth.
Adjusted EBITDA guidance was increased to $700 million to $740 million from $620 million to $660 million, representing expected growth of 68% compared to 2025. Non-GAAP operating expenses guidance remained unchanged at $430 million to $450 million, reflecting the company’s commitment to cost discipline while investing in growth initiatives.
Forward-Looking Considerations
While Indivior’s operational execution and financial performance have been strong, several factors warrant investor attention. The company’s growth remains heavily concentrated in SUBLOCADE, which accounted for approximately 74% of total net revenue in the quarter. Any competitive pressure or market dynamics affecting the product could have material impacts on overall results.
The proposed Supernus merger introduces integration risks and execution challenges, even as it promises diversification and scale benefits. The transaction requires shareholder and regulatory approvals, and the realization of projected cost synergies will depend on successful integration of operations, systems, and cultures.
Competition in the opioid use disorder treatment market continues to evolve, with alternative long-acting injectable products and potential new entrants representing ongoing competitive threats. Additionally, the company’s projection that long-acting injectables will capture greater market share from oral buprenorphine products assumes continued acceptance by healthcare providers and patients, which may face headwinds from cost considerations, access barriers, or clinical preferences.
Despite these considerations, Indivior’s second-quarter results demonstrate substantial progress in executing its strategic plan, with margin expansion, cash generation, and market share gains in SUBLOCADE providing a foundation for the next phase of growth through the Supernus combination.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.